Taranabant Phase III study shows substantial weight loss
According to the data from Phase III study of Merck’s taranabant, obese patients taking the drug experienced substantial weight loss when the drug was combined with diet and exercise. Patients who were taking 2 mg of taranabant during the study reported double the weight loss compared to patients being treated with placebo.
- Merck & Co. drops taranabant for treating obesity
- Weight loss surgery in teens improves heart functioning
- Orexigen’s Empatic and Contrave give positive results
- FDA Seeks Recall Of 25 Weight Loss Pills With Potentially Unsafe Ingredients
